Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126577792 | 12657779 | 2 | F | 20160818 | 20160816 | 20160818 | EXP | JP-JNJFOC-20160809506 | JANSSEN | OCHI Y, HIRAMOTO N, ONO Y, YOSHIOKA S, TABATA S, YONETANI N, ET AL. TOLERABILITY AND EFFICACY OF RITUXIMAB-CONTAINING IMMUNOCHEMOTHERAPY IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA RECEIVING HEMODIALYSIS. LEUKEMIA AND LYMPHOMA 02-AUG-2016;57/8:1945-1948. | 60.00 | YR | M | Y | 0.00000 | 20160818 | OT | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126577792 | 12657779 | 1 | PS | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | N | 50718 | 50 | MG/M**2 | LIPOSOME INJECTION | |||||||
| 126577792 | 12657779 | 2 | SS | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | U | 0 | 50 | MG/M**2 | LIPOSOME INJECTION | |||||||
| 126577792 | 12657779 | 3 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | U | 0 | 750 | MG/M**2 | UNSPECIFIED | |||||||
| 126577792 | 12657779 | 4 | SS | VINCRISTINE | VINCRISTINE | 1 | Intravenous (not otherwise specified) | U | 0 | 1.4 | MG/M**2 | UNSPECIFIED | |||||||
| 126577792 | 12657779 | 5 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Oral | U | 0 | 100 | MG | UNSPECIFIED | |||||||
| 126577792 | 12657779 | 6 | SS | RITUXIMAB | RITUXIMAB | 1 | Intravenous (not otherwise specified) | U | 0 | 375 | MG/M**2 | UNSPECIFIED |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126577792 | 12657779 | 1 | Lymphoma |
| 126577792 | 12657779 | 2 | Lymphoma |
| 126577792 | 12657779 | 3 | Lymphoma |
| 126577792 | 12657779 | 4 | Lymphoma |
| 126577792 | 12657779 | 5 | Lymphoma |
| 126577792 | 12657779 | 6 | Lymphoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126577792 | 12657779 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126577792 | 12657779 | Anaemia | |
| 126577792 | 12657779 | Infection | |
| 126577792 | 12657779 | Neuropathy peripheral | |
| 126577792 | 12657779 | Neutropenia | |
| 126577792 | 12657779 | Off label use | |
| 126577792 | 12657779 | Product use issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |